Journal of Oncology

Research Article

Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Cohort Study

Table 2

Univariate and multivariate analysis of local tumor control, progression-free survival, and overall survival.


Variable	Local tumor control				Progression-free survival				Overall survival
	Univariate		Multivariate^†		Univariate		Multivariate^†		Univariate		Multivariate^†
	HR (95% CI)		HR		HR		HR		HR		HR

Age (years)^‡	0.61 (0.11–3.34)	0.56	—	—	1.19 (0.40–3.54)	0.76	—	—	3.45 (0.66–18.02)	0.14	—	—
BMI (kg/m²)^‡	1.08 (0.22–5.39)	0.92	—	—	0.99 (0.33–2.94)	0.98	—	—	0.33 (0.06–1.75)	0.19	—	—
Cirrhosis	0.55 (0.10–3.00)	0.49	NA	NA	0.97 (0.32–2.88)	0.95	NA	NA	0.86 (0.19–3.88)	0.85	—	—
Antivirus	1.22 (0.22–6.70)	0.82	—	—	1.41 (0.43–4.58)	0.57	—	—	0.81 (0.21–6.32)	0.78	—	—
CP score	4.54 (0.74–28.11)	0.10	NA	NA	5.17 (1.43–18.64)	0.012	5.17 (1.43–18.64)	0.012	1.43 (0.17–12.05)	0.74	—	—
No. of prior^‡	12.86 (1.46–113.0)	0.02	11.69 (1.35, 101.4)	0.026	2.27 (0.76–6.83)	0.14	NA	NA	1.73 (0.39–7.81)	0.47	—	—
Perivessel	0.29 (0.06–1.46)	0.13	NA	NA	0.63 (0.19–2.07)	0.45	—	—	0.43 (0.10–1.94)	0.27	—	—
Subcapsular	1.71 (0.31–9.40)	0.54			0.98 (0.27–3.56)	0.97	—	—	1.71 (0.33–8.83)	0.52	—	—
Diameter (mm)	0.90 (0.16–5.00)	0.91	NA	NA	1.34 (0.45–3.99)	0.60	NA	NA	3.05 (0.59–15.83)	0.19	—	—
Dose to PTV^‡	1.34 (0.27–6.69)	0.72	—	—	1.11 (0.37–3.29)	0.86	—	—	0.51 (0.10–2.64)	0.42	—	—
AFP (ng/ml)^§	1.74 (0.34–8.85)	0.51	NA	NA	1.59 (0.51–4.96)	0.43	NA	NA	0.83 (0.16–4.46)	0.83	—	—
AD	NA	0.46	—	—	3.04 (0.39–23.48)	0.29	—	—	1.95 (0.23, 16.49)	0.54	—	—
LTC	—	—	—	—	—	—	—	—	0.85 (0.10–7.10)	0.88	—	—

BMI, body mass index; CP score, child-Pugh score; no. of prior, number of prior treatments; PTV, patient-specific planning target volume; AFP, alpha-fetoprotein; AD, adverse events; LTC, local tumor control; NA, not applicable. † Variables with values less than 0.1 in univariate analysis and those that may have an impact on tumor progression or survival based on clinical experience were included in the multivariate analysis using the forward LR method. ‡ For the variables age, BMI, number of prior treatments, and dose to the PTV, patients were dichotomized by the median values to transform quantitative data into two-category data. § Patients were divided into the low-AFP group (serum AFP < 200 ng/ml before SBRT) and the high-AFP group (serum AFP ≥ 200 ng/ml before SBRT).